BioNTech’s latest push into infectious disease comes with a dual dose of promise and peril. The German biotech is set to launch a phase I/II clinical trial for BNT168, a therapeutic mRNA vaccine candidate targeting HIV, in July 2026 — while simultaneously facing fresh patent litigation over the lipid nanoparticle technology that underpins its COVID-19 vaccine. The confluence of scientific ambition and legal uncertainty underscores the complexity of the company’s transformation from pandemic winner to diversified biotechnology player.
The HIV study, registered under identifier NCT07698600, will enroll 126 participants. Three cohorts will consist of HIV-negative volunteers receiving three injections, while two additional cohorts will include HIV-positive patients who have been on stable antiretroviral therapy for at least 12 months and will receive four doses. The trial’s primary goal is to determine whether a vaccine-induced immune response can maintain viral suppression even after antiretroviral therapy is paused. If successful, it would represent one of the first randomized demonstrations of a therapeutic mRNA approach against HIV, potentially freeing patients from lifelong medication. Results are not expected until the trial concludes in January 2028.
The new legal front opened by Arbutus Biopharma and Genevant Sciences targets the same lipid nanoparticle delivery system that made BioNTech’s COVID shot a blockbuster. Any adverse ruling could impose additional financial burdens on a business already grappling with a dramatic revenue decline. At the pandemic’s peak in 2022, BioNTech recorded €17.3 billion in sales; by 2025, that figure had fallen to €2.87 billion. The patent suits inject a further element of uncertainty into a core technology that investors had long considered settled.
Financially, BioNTech has built a cushion for its transition. The company held €16.7 billion in cash and equivalents as of the third quarter of 2025, bolstered in part by an upfront payment from its collaboration with Bristol Myers Squibb. Yet the investment phase is taking its toll: in the first quarter of 2026, revenue of €118.1 million was overshadowed by a net loss of €531.9 million, reflecting heavy spending across oncology programs, infectious disease research, and the build-out of commercial infrastructure. Management has pledged to maintain cost discipline even as development outlays rise.
Should investors sell immediately? Or is it worth buying BioNTech?
The stock market greeted the news with a shrug rather than a stampede. Shares closed Friday at €80.20, up a modest 0.25% on the day but still 24% below the 52-week high of €105.80 reached on January 22. The relative strength index of 49.3 points to neutral sentiment, while the stock’s 5.54% discount to the 200-day moving average of €84.90 suggests the medium-term trend remains subdued. Analysts are split on the outlook, with no clear consensus emerging as investors weigh the long-term promise of the oncology pipeline against near-term revenue erosion and legal overhangs.
BioNTech now runs more than 20 product candidates, eight of which are in clinical trials. Founded in 2008 as a spin-off from Johannes Gutenberg University Mainz, the company employs over 2,800 people across Germany, Austria, and the United States. While the founders Ugur Şahin and Özlem Türeci received Germany’s Federal Cross of Merit in March 2021 at the height of public acclaim, the spotlight has since dimmed. The HIV trial, along with the oncology push that Chief Commercial Officer Annemarie Hanekamp has described as “appropriately dimensioned” market launches, will determine whether BioNTech can replicate its COVID-era success in a less frantic, more fragmented therapeutic landscape.
For now, the waiting game continues. The HIV data is years away, the patent cases are unresolved, and the COVID revenue stream continues to shrink. The stock’s sideways movement reflects a market content to sit on its hands until either the legal clouds lift or the pipeline delivers a blockbuster.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 20 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 20.
BioNTech: Buy or sell? Read more here...
